更新于：2024-11-15
Teicoplanin
替考拉宁
更新于：2024-11-15
概要
基本信息
关联
37
项与 替考拉宁 相关的临床试验Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)
A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care
Population Pharmacokinetics of Teicoplanin in Hypoalbuminemia Population
100 项与 替考拉宁 相关的临床结果
登录后查看更多信息
100 项与 替考拉宁 相关的转化医学
登录后查看更多信息
100 项与 替考拉宁 相关的专利（医药）
登录后查看更多信息
4,052
项与 替考拉宁 相关的文献（医药）2024-12-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Chiral superficially porous stationary phases for enantiomeric separation of condensed 1,4-dihydropyridine derivatives
Article
作者: Armstrong, Daniel W ; Burk, Ryan Jacob ; Salehi, Reza ; Gündüz, Miyase Gözde ; J, Siddharth Jaya Sajeevan ; Berthod, Alain ; Armstrong, Daniel W.
1,4-dihydropyridine (DHP) scaffold occupies a prominent position among all heterocyclic compounds owing to its versatile pharmacological properties, particularly its well-known calcium channel blocking activity. In the quest of developing new calcium channel blockers, fifty seven 5-oxo-hexahydroquinoline (HHQ) derivatives carrying DHP framework in a condensed ring system were recently synthesized as racemic mixtures. Due to their potential as drug candidates, enantiomers arising from the asymmetric center at the C-4 position of the HHQ ring were separated. Four modern columns packed with 2.7 µm superficially porous particles bonded with a chiral selector were used. The chiral selectors were three macrocyclic glycopeptide selectors: vancomycin, teicoplanin, and a macrocyclic derivative called nico. The fourth bonded selector was the dinitrobenzamido-tetrahydrophenanthrenyl derivative called Whelko. The four chromatographic modes were assayed with the mobile phase compositions: reversed phase with acetonitrile/buffer 30/70 %v/v, normal phase with hexane/ethanol 80/20 %v/v, and subcritical fluid chromatography with CO2/methanol 80/20 %v/v at 25 °C. The WhelkoShell column was the most effective in separating this set of 57 compounds. Several enantioresolution factors passed 20 with enantioselectivity ratios higher than 4. Molecular modeling showed that the compounds had a T-shape that fitted well the molecular structure of the WhelkoShell selector in the normal or subcritical modes. Additionally, seven compounds had a second chiral center. The NicoShell column was able to separate all four stereoisomers of these compounds in the reversed phase mode. The preparative production of pure enantiomers of these compounds would be straightforward using the WhelkoShell column in the subcritical mode.
2024-11-04JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre
Article
作者: Villamarín, Miguel ; Fernández-Hidalgo, Nuria ; González-López, Juan José ; Viñado, Belén ; Rello, Pau ; Escolà-Vergé, Laura
Abstract:
Objectives:
Clinical experience in the use of teicoplanin for treating enterococcal infective endocarditis (EIE) is scarce. The aim of this study was to describe the characteristics and outcomes of patients with EIE treated with teicoplanin monotherapy compared to standard therapy with ampicillin plus ceftriaxone.
Methods:
All consecutive adult patients diagnosed with EIE between January 2018 and September 2022 at a referral centre were reviewed. Characteristics of individuals treated with teicoplanin for ≥14 days [the treated with teicoplanin (TT) group] were compared with those who received ampicillin plus ceftriaxone (AC group).
Results:
Sixty-six patients were included [61 (92%) E. faecalis infective endocarditis (IE) and 5 (8%) E. faecium IE]. Twenty-seven (41%) received teicoplanin: eight as first-line treatment and 19 as continuation therapy.The median duration of teicoplanin treatment was 30 (25–43) days. Surgery was indicated in 14/27 (52%) in the TT group and in 21/39 (54%) in the AC group, but was finally performed in 11/14 (79%) and 13/21 (62%) (P = 0.46), respectively. In-hospital mortality rate was 3/27 (11%) in the TT group and 12/39 (31%) in the AC group (P = 0.06). Patients treated with teicoplanin were more often discharged on outpatient parenteral antibiotic therapy [18/27 (67%) versus 6/39 (15%), P < 0.001] and median hospital stay was shorter [29 days (IQR 20–61) versus 50 days (IQR 43–68), P = 0.006]. One-year cumulative mortality was 8/27 (30%) in the TT group and 13/39 (33%) in the AC group (P = 0.46). There was one relapse in each group.
Conclusion:
Teicoplanin seems an effective treatment for selected patients with enterococcal IE, mainly to facilitate discharge.
2024-11-01Biomaterials advances
Tricalcium phosphate-loaded injectable hydrogel as a promising osteogenic and bactericidal teicoplanin-delivery system for osteomyelitis treatment: An in vitro and in vivo investigation
Article
作者: Kai, Karen Cristina ; Borges, Roger ; Pelosine, Agatha Maria ; da Cunha, Marcelo Rodrigues ; Pedroni, Ana Clara Fagundes ; Marques, Marcia Martins ; de Araújo, Daniele Ribeiro ; Marchi, Juliana
Osteomyelitis is an inflammation of bone tissue usually caused by pyogenic bacteria. The most recurrent clinical approach consists of bone debridement followed by parenteral administration of antibiotics. However, systemic antibiotic treatment has limitations regarding absorption rate and bioavailability over time. The main challenge of osteomyelitis treatment consists of coupling the persistent infection treatment with the regeneration of the bone debrided. In this work, we developed an injectable drug delivery system based on poloxamer 407 hydrogel containing undoped Mg, Zn-doped tricalcium phosphate (β-TCP), and teicoplanin, a broad-spectrum antibiotic. We evaluated how the addition of teicoplanin and β-TCP affected the micellization, gelation, particle size, and surface charge of the hydrogel. Later, we studied the hydrogel degradation and drug delivery kinetics. Finally, the bactericidal, biocompatibility, and osteogenic properties were evaluated through in vitro studies and confirmed by in vivo Wistar rat models. Teicoplanin was found to be encapsulated in the corona portions of the hydrogel micelles, yielding a bigger hydrodynamics radius. The encapsulated teicoplanin showed a sustained release over the evaluated period, enough to trigger antibacterial properties against Gram-positive bacteria. Besides, the formulations were biocompatible and showed bone healing ability and osteogenic properties. Finally, in vivo studies confirmed that the proposed locally injected formulations yielded osteomyelitis treatment with superior outcomes than parenteral administration while promoting bone regeneration. In conclusion, the presented formulations are promising drug delivery systems for osteomyelitis treatment and deserve further technological improvements.
100 项与 替考拉宁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脓胸 | 日本 | 1998-04-10 | |
| 出血性败血症 | 日本 | 1998-04-10 | |
| 肺炎 | 日本 | 1998-04-10 | |
| 皮肤和皮肤结构感染 | 日本 | 1998-04-10 | |
| 革兰氏阳性细菌感染 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 埃博拉病毒性疾病 | 临床前 | 中国 | 2016-04-01 | |
| 严重急性呼吸综合征 | 临床前 | 中国 | 2016-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | 淵顧鬱鏇廠淵衊製積範(餘觸選範醖齋餘餘鬱鬱) = 顧蓋鏇網廠鹹願簾膚選 繭艱蓋糧鏇齋獵鹽鹽夢 (憲鬱選廠鏇鏇醖壓壓鬱 ) 更多 | 积极 | 2009-11-01 | |||
淵顧鬱鏇廠淵衊製積範(餘觸選範醖齋餘餘鬱鬱) = 壓選齋衊顧餘壓構窪鏇 繭艱蓋糧鏇齋獵鹽鹽夢 (憲鬱選廠鏇鏇醖壓壓鬱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用